P16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma

American Journal of Surgical Pathology

Volumn 38, Issue 5, 2014, Pages 681-688

  Hwang, Harry ^a   Tse, Christopher ^a   Rodriguez, Stephanie ^a   Gown, Allen ^a   Churg, Andrew ^b  

^a PHENOPATH LABORATORIES   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

atypical mesothelial proliferation; malignant mesothelioma; p16 FISH

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ARTICLE; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETICS; HUMAN; MESOTHELIOMA; TUMOR SUPPRESSOR GENE;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MESOTHELIOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84899493374     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000176     Document Type: Article

References (14)

1. Churg A, Colby TV, Cagle P, et al. The separation of benign andmalignant mesothelial proliferations. Am J Surg Pathol.2000;24:1183-1200.
2. Churg A, Galateau-Salle F. The separation of benign andmalignant mesothelial proliferations. Arch Pathol Lab Med. 2012;136:1217-1226.
3. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologicdiagnosis of malignant mesothelioma: 2012 update of the consensusstatement from the International Mesothelioma Interest Group.Arch Pathol Lab Med. 2013;137:647-667.
4. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletionas a diagnostic marker for malignant mesothelioma in body cavityeffusions. Cancer. 2003;99:51-56. (Pubitemid 36267967)
5. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of9p21 homozygous deletion in malignant mesotheliomas. ModPathol. 2008;21:742-757.
6. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16FISH and GLUT-1 immunohistochemical analysis in mesothelialproliferations. Am J Clin Pathol. 2011;135:619-627.
7. Chung CT, Santos Gda C, Hwang DM, et al. FISH assaydevelopment for the detection of p16/CDKN2A deletion inmalignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
8. Tochigi N, Attanoos R, Chirieac LR, et al. p16 Deletion insarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med.2013;137:632-636.
9. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness ofp16/CDKN2A FISH in distinguishing between sarcomatoid mesotheliomaand fibrous pleuritis. Am J Clin Pathol. 2013;139:39-46.
10. Cao C, Yan TD, Deraco M, et al. Importance of gender indiffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23:1494-1498.
11. Henderson DW, Reid G, Kao SC, et al. Challenges andcontroversies in the diagnosis of mesothelioma: Part 1. Cytologyonlydiagnosis, biopsies, immunohistochemistry, discriminationbetween mesothelioma and reactive mesothelial hyperplasia, andbiomarkers. J Clin Pathol. 2013;66:847-853.
12. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity ofimmunohistochemical antibodies used to distinguish between benignand malignant pleural disease: a systematic review of publishedreports. Histopathology. 2006;49:561-568. (Pubitemid 44924287)
13. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistryfor distinguishing benign from malignant mesothelialproliferations. Am J Surg Pathol. 2013;37:421-426.
14. Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion ofCDKN2A and codeletion of the methylthioadenosine phosphorylasegene in the majority of pleural mesotheliomas. Clin CancerRes. 2003;9:2108-2113. (Pubitemid 36687632)